Early Surgical Laser-Assisted Management of Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ): A Retrospective Analysis of 101 Treated Sites with Long-Term Follow-Up
- 1 January 2012
- journal article
- research article
- Published by Mary Ann Liebert Inc in Photomedicine and Laser Surgery
- Vol. 30 (1), 5-13
- https://doi.org/10.1089/pho.2010.2955
Abstract
Background data: The management of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is still controversial. Objective: The purpose of this study was to compare surgical and nonsurgical approaches to the treatment of BRONJ and the possible usefulness of Nd:YAG and Er:YAG lasers. Methods: One hundred and twenty-eight patients (33 males, 95 females; 52 with diagnosis of multiple myeloma, 53 with diagnosis of bone metastasis, and 23 with diagnosis of osteoporosis) affected by BRONJ were evaluated at the Unit of Oral Pathology and Medicine and Laser-Assisted Surgery of the University of Parma, Italy, between January 2004 and July 2009. Overall number of BRONJ sites was 151, and number of treated sites was 101. In order to assess the efficacy of different treatments, sites were subclassified as follows: Group 1 (G1): 12 sites treated with medical therapy; Group 2 (G2): 27 sites treated with medical therapy associated with low level laser therapy (LLLT); Group 3 (G3): 17 sites treated with a combination of medical and surgical therapy; Group 4 (G4): 45 sites treated with a combination of medical therapy, surgical (including laser-assisted) therapy, and LLLT. Outcome of treatment was assessed using the staging system proposed by Ruggiero et al. Transition from a higher stage to a lower one for at least 6 months was considered as clinical improvement and suggestive of a successful treatment. Results: Clinical improvement was achieved in 3 out of 12 (25%) BRONJ sites in G1. Sites if G2 with an improvement were 18 out of 27 (66%). Nine out 17 BRONJ sites (53%) in G3 had a transition to a lower stage after treatment. For sites in G4, a clinical improvement was recorded in 40 out of 45 cases (89%). Conclusions: In our experience, the percentage of success obtained with a combined approach based on medical therapy, surgical (including laser-assisted) therapy, and LLLT (G4) is significantly higher than the percentage of improvement obtained in G1, G2, and G3.Keywords
This publication has 45 references indexed in Scilit:
- Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I–II studyOral Oncology, 2011
- Editorial BoardJournal of Oral and Maxillofacial Surgery, 2009
- Utility of Hyperbaric Oxygen in Treatment of Bisphosphonate-Related Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2009
- Zoledronic acid in the management of metastatic bone diseaseExpert Opinion on Biological Therapy, 2006
- Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and managementOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2006
- Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacyBone, 2006
- Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With CancerJournal of Oncology Practice, 2006
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Avascular necrosis of the jaws: risk factors in metastatic cancer patientsJournal of Oral and Maxillofacial Surgery, 2003
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003